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2Dipartimento di Scienze Motorie e della Salute, Università di Cassino, Cassino, Italy; 3Department of Microbiology and
Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA and 4IGM-CNR, Sezione di Bologna c/o
I.O.R., Bologna, Italy
A significant impediment to the success of cancer chemotherapy
is the occurrence of multidrug resistance, which, in many
cases, is attributable to overexpression of membrane transport
proteins, such as the 170-kDa P-glycoprotein (P-gp). Also,
upregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt-
signaling pathway is known to play an important role in drug
resistance, and has been implicated in the aggressiveness of a
number of different cancers, including T-acute lymphoblastic
leukemia (T-ALL). We have investigated the therapeutic poten-
tial of the novel Akt inhibitor, perifosine (a synthetic alkylphos-
pholipid), on human T-ALL CEM cells (CEM-R), characterized by
both overexpression of P-gp and constitutive upregulation
of the PI3K/Akt network. Perifosine treatment induced death
by apoptosis in CEM-R cells. Apoptosis was characterized by
caspase activation, Bid cleavage and cytochrome c release from
mitochondria. The proapoptotic effect of perifosine was in part
dependent on the Fas/FasL interactions and c-Jun NH2-terminal
kinase (JNK) activation, as well as on the integrity of lipid rafts.
Perifosine downregulated the expression of P-gp mRNA and
protein and this effect required JNK activity. Our findings
indicate that perifosine is a promising therapeutic agent for
treatment of T-ALL cases characterized by both upregulation of
the PI3K/Akt survival pathway and overexpression of P-gp.
Leukemia (2008) 22, 1106–1116; doi:10.1038/leu.2008.79;
published online 3 April 2008
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Introduction
Despite improvement in chemotherapy strategies, the develop-
ment of multidrug resistance (MDR) remains one of the major
problems in chemotherapy.1 MDR is a complex phenomenon,
often associated with overexpression of the 170-kDa P-
glycoprotein (P-gp) on the plasma membrane of tumor cells.
P-gp is the product of the ABCB1 (MDR1) gene and belongs to
the superfamily of ATP-binding cassette transporters, which
actively efflux across the membranes a wide range of structurally
diverse compounds used to treat cancer, thus reducing their
intracellular bioavailability and toxicity.2 P-gp overexpression
correlates with poor prognosis for many human cancers.3 In
addition, it is well known that P-gp overexpression confers
resistance to a wide range of caspase-dependent proapoptotic
agents, not only by removing drugs from the cells, but also by
inhibiting the activation of caspases, a family of proteases,
which are key players in apoptotic cell death.4 Only a few drugs
are reported to overcome the MDR phenotype induced by this
ATP-binding cassette transporter,5 and most of them induce cell
death in a caspase-independent manner,6 albeit a few drugs are
capable of activating caspases in P-gp-expressing cells.7
Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt-
signaling pathway is another key factor, which plays a central role
in cancer biology, conferring resistance both in vivo and in vitro
to therapeutic treatments of various types of malignancies.8–10
Upon activation by different stimuli, membrane localization of
PI3K generates phosphatidylinositol-3,4,5-trisphosphate, which
then activates a number of downstream substrates.11 The serine/
threonine kinase Akt is a well-characterized PI3K target, and
binding of phosphatidylinositol-3,4,5-trisphosphate to the pleck-
strin homology domain of Akt results in its translocation to the
plasma membrane, where it undergoes phosphorylation at both
Thr308 and Ser473. A fundamental negative regulator of the PI3K/
Akt pathway is the lipid phosphatase PTEN (phosphatase and
tensin homolog deleted on chromosome 10), which removes the
3-phosphate from phosphatidylinositol-3,4,5-trisphosphate, thus
yielding PtdIns 4,5 P2.
12 Small inhibitory molecules of the PI3K/
Akt pathway are currently being developed for clinical use.13
Indeed, over the last few years, several Akt inhibitors have been
synthesized, including perifosine, a novel alkylphospholipid
analog, which has shown promising preclinical activity and is
currently undergoing phase-I/II clinical evaluation.14,15 Although
mechanisms underlying the anticancer activity of perifosine
remain to be fully elucidated, perifosine, via interference with
the turnover and synthesis of natural phospholipids, disrupts
membrane-linked signaling pathways at several sites, thereby
inhibiting PI3K/Akt.16 Perifosine inhibits Akt phosphorylation by
its interaction with the pleckstrin homology domain of the kinase,
thus preventing Akt membrane localization and phosphoryla-
tion.14 Perifosine, in some cell types, downregulates the
antiapoptotic extracellular signal-regulated kinase (ERK) 1/2
pathway17 and activates the proapoptotic c-Jun NH2-terminal
kinase (JNK) network, thereby altering the balance between the
survival- and death-signaling cascades.18 From a clinical
perspective, perifosine is the most developed PI3K/Akt inhibitor.19
We have recently reported the cytotoxic effect of perifosine alone,
or combined with etoposide, on the PTEN-null Jurkat T-acute
lymphoblastic leukemia (T-ALL) cell line.20 However, the
cytotoxic activity of perifosine has not been tested on cells,
which overexpress P-gp in combination with a constitutively
active PI3K/Akt network.
In the following studies, we demonstrated that perifosine is
cytotoxic for human T-ALL CEM-R cells, which are characterized
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by overexpression of P-gp and upregulation of the PI3K/Akt-
signaling network due to absence of PTEN expression.21 Remark-
ably, exposure to perifosine resulted in activation of caspases in
CEM-R cells. Perifosine-dependent apoptotic cell death of CEM-R
cells was also characterized by JNK activation and was partly
dependent on Fas ligation and disruption of lipid raft integrity. In
summary, our results indicate that perifosine is a promising drug
also for treatment of P-gp-overexpressing neoplastic hematopoietic
disorders characterized by PI3K/Akt signaling upregulation.
Materials and methods
Materials
Perifosine was provided by AEterna Zentaris GmbH (Frankfurt,
Germany). For cell viability determination, Cell Proliferation kit
I (3-[4,5-dimethylthythiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT)) was purchased from Roche Applied Science
(Penzberg, Germany) and Annexin V staining kit was purchased
from Bender MedSystem (Wien, Austria), whereas Carboxy-
fluorescein Fluorescent-Labeled Inhibitor of Caspases (FLICA)
Apoptosis Detection kit Caspase Assay was from AbD Serotec
(Oxford, UK). Antibodies were from Cell Signaling Technology
(Danvers, MA, USA) (Akt, Ser473 p-Akt, Thr308 p-Akt, ERK 1/2,
Thr202/Tyr204 p-ERK 1/2, JNK, Thr183/Tyr185 p-JNK, caspase-
3, caspase-8, caspase-9, poly-(ADPribose)-polymerase (PARP),
b-actin, cytochrome c, cytochrome c oxidase IV). The two-color
fluorescence immunocytochemistry detection kit for cyto-
chrome c and mitochondria was from MitoSciences (Eugene,
OR, USA). Mouse monoclonal blocking antibody to human Fas
(SM1/23) was from Alexis Biochemicals (Lausen, Switzerland),
whereas anti-Fas antibody for immunocytochemical staining
(SM1/1) was from Bender MedSystem. The cell-permeable JNK
inhibitor (SP600125), the caspase-3 inhibitor (Z-DEVD-FMK)
and the caspase-8 inhibitor (Z-IETD-FMK) were from Calbio-
chem-Novabiochem (La Jolla, CA, USA). Methyl-b-cyclodextrin
(MCD), fluorescein isothiocyanate (FITC)-labeled cholera toxin B
(FITC-CTx B) subunit, vinblastine, anti-P-gp antibody (clone F4)
and Trypan Blue were from Sigma-Aldrich (St Louis, MO, USA).
Cell culture
The parental drug-sensitive human T-lymphoblastic CEM cell
line (CEM-S, for sensitive) and its P-gp-expressing variant (CEM-
R, for resistant)21 were grown in RPMI 1640 medium,
supplemented with 10% heat-inactivated fetal bovine serum.
MDR-variant CEM-R cells were supplemented once a week with
100 ng ml1 of vinblastine. To determine cell growth, 3 105
cells were seeded in 25-cm2 flasks and growth curves were
prepared by plotting direct counts of cells harvested for 5 days
after seeding. Viable cells counts were counted by a hemocyto-
meter using 0.2% Trypan Blue.
Cell viability analysis
3-[4,5-Dimethylthythiazol-2-yl]-2,5-diphenyltetrazolium bromide
assays were performed to assess the sensitivity of CEM cells to
perifosine, as previously reported.20 Results were statistically
analyzed by GraphPadPrism Software (version 3.2; GraphPad
Software Inc., San Diego, CA, USA).
Annexin V–FITC/PI staining
To assess the extent of apoptosis induction after treatment with
perifosine, a flow cytometric analysis of Annexin V–FITC/
propidium iodide (PI)-stained samples was performed, as
reported elsewhere.20 Samples were analyzed with the EPICS
XL flow cytometer (Beckman Coulter, Miami, FL, USA) with the
appropriate software (System II; Beckman Coulter). At least
15 000 events per sample were acquired.
Western blotting analysis
This was performed as reported elsewhere.22 Quantitation of
blots by scanning was performed as previously reported.23
Figure 1 Perifosine cytotoxicity and apoptosis induction in CEM cells. (a) MTT assays of CEM-R and CEM-S cells cultured with perifosine for 24 h.
Results are the mean of three different experiments±s.e. The asterisk indicates statistically significant difference (Po0.005) with respect to
untreated cells. (b) Western blot analysis showing Ser473 p-Akt and total Akt levels in CEM-R and CEM-S cells. The molecular weight of the
antigens is indicated at right. The antibody to b-actin demonstrated equal loading in the lanes. The numbers indicate the results from densitometric
analysis. One representative of three different experiments is shown. (c) Representative histograms showing flow cytometric analysis of Annexin V–
FITC/PI-stained CEM cells. Cells were cultured with perifosine (20mM for CEM-R and 7 mM for CEM-S) for the indicated time periods. The
percentage of early apoptotic cells (lower right quadrant) and late apoptotic/necrotic cells (upper right quadrant) is indicated. One representative of
three different experiments is shown. FITC, fluorescein isothiocyanate; MTT, 3-[4,5-dimethylthythiazol-2-yl]-2,5-diphenyltetrazolium bromide; PI,
propidium iodide.
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Isolation of mitochondrial fraction
This was accomplished using the Mitochondria Isolation kit
(Pierce, Rockford, IL, USA), according to the manufacturer’s
instructions.
Caspase activity assay
Flow cytometric assays were performed, to determine caspase
activity, using the Carboxyfluorescein FLICA Apoptosis Detec-
tion kit Caspase Assay, according to the manufacturer’s
instructions. After treatments, cells were collected by centrifu-
gation and washed in phosphate-buffered saline (PBS). A total of
3 105 cells per sample were labeled with the FLICA solution
and incubated for 1 h at 37 1C and washed twice in PBS.
Fluorescence resulting from the FLICA regent was measured at
488 nm by flow cytometry.
Fluorescence immunocytochemistry
Cells were collected by centrifugation at a density of
3 105 cells ml1 and plated on electrostatically charged glass
slides, using a Shandon Cytospin (Thermo Electron Corporation,
Figure 2 Perifosine negatively affects cell proliferation rates of CEM cells and p-Akt levels. (a) To determine cell growth, 3105 cells were
seeded in 25-cm2 flasks and growth curves were generated by plotting direct count of cells harvested for 5 days after seeding. Viable cells counts
were counted by a hemocytometer using 0.2% Trypan Blue. In some experiments, cells were washed with serum-free medium and incubated in
complete medium to which perifosine was added to the original concentration (renewal). Results are the mean of three different experiments±s.e.
The asterisk indicates statistically significant difference (Po0.005) with respect to untreated cells (CTRL). (b) Western blot analysis. Cells were
cultured for an increasing period of time in the presence of 20mM perifosine. Whole-cell extracts were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and electrotransferred to nitrocellulose membranes, which were then probed with the indicated antibodies.
The molecular weight of the antigens is indicated at right. The antibody to b-actin demonstrated equal loading in the lanes. One representative of
three different experiments is shown.
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Pittsburgh, PA, USA). Samples were fixed with 4% formal-
dehyde in PBS, pH 7.4, for 10 min at room temperature and
subsequently permeabilized with 0.2% Triton X-100 in PBS for
5 min. After two washes with PBS, the slides were saturated in
PBS 5% bovine serum albumin for 1 h at room temperature.
Detection of cleaved caspase-3. Cells were treated as
outlined above, and then reacted with an antibody to cleaved
caspase-3 (from Cell Signaling), which was then revealed with
an FITC-conjugated anti-rabbit antibody.
Two-color immunocytochemistry of cytochrome c and
mitochondrial colocalization. This was accomplished
using an anti-cytochrome c antibody (IgG2a isotype, which
was detected by a goat anti-mouse IgG2a antibody conjugated
to FITC) and by an anti-Complex V subunit monoclonal
antibody (IgG2b isotype, which was detected by a goat anti-
mouse IgG2b antibody conjugated to Texas Red).
Visualization of lipid rafts. Samples were incubated with
8 mg ml1 of FITC-CTx B subunit diluted in PBS 1% bovine
serum albumin for overnight at 4 1C in the dark, and washed
three times with PBS. For colocalization experiments, FITC-CTx
B subunit staining was performed as described above, but
samples were incubated also with 500 ng ml1 of anti-human
Fas (SM1/1) IgG2a mouse monoclonal antibody at 4 1C.
Samples were further processed using Cy3-conjugated anti-
mouse IgG antibody, diluted 1:500, to detect Fas. To visualize
Figure 3 Perifosine activates both the extrinsic and intrinsic apoptotic pathway in CEM-R cells. (a) Western blot analysis showing cleavage of
caspase-8, caspase-9, caspase-3, Bid and PARP in response to 20mM perifosine. Molecular weights are indicated to the right. One representative of
three different experiments is shown. (b) Caspase activity was analyzed by the FLICA assay. Cells were cultured for the indicated time periods in
the presence of 20mM perifosine. One representative of three different experiments is shown. (c) Immunofluorescence analysis demonstrating
cleavage of caspase-3 in cells treated for 6 h with 20mM perifosine. Cells were stained with an antibody, which specifically recognizes caspase-3
cleaved at Asp175, which was then revealed by an FITC-conjugated secondary antibody. Nuclei were counterstained for DNA by 40,6-diamidino-
2-phenylindole. (d) Caspase inhibitors decrease apoptotic cell death evoked by perifosine. Cells were preincubated for 2 h with 20mM of either
caspase-3 inhibitor Z-DEVD-FMK, or caspase-8 inhibitor Z-IETD-FMK, treated with perifosine and then subjected to flow cytometric analysis of
Annexin V–FITC/PI staining. One representative of three different experiments is shown. CTRL, control; DAPI, 40,6-diamidino-2-phenylindole;
FITC, fluorescein isothiocyanate; FLICA, Fluorescent-Labeled Inhibitor of Caspases.
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nuclei, samples were incubated for 1 min with 40,6-diamidino-2-
phenylindole (0.5 mg ml1, DAPI). Finally, slides were examined
under epifluorescent illumination. Images were taken with a
Zeiss Axio Imager.Z1 microscope coupled to a computer-driven
Zeiss AxioCAM digital camera (MRm), using Zeiss AxioVision
software (version 4.5) and the Zeiss colocalization module with
constant settings of exposure.
Electrophoretic mobility-shift assay
This was performed according to Faenza et al.24 A double-
stranded oligonucleotide containing the consensus binding site
for Activator Protein 1 (AP1), 50-CGCTTGATGACTCAGCCG
GAA-30 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was used as a probe for the assay. The probe was labeled with
[g-32P]dATP (3000 Ci mmol1; Perkin Elmer, Whaltam, MA,
USA) using T4 polynucleotide kinase. A 10-mg weight of
nuclear extract was used for each binding reaction. Where
appropriate, the extract was preincubated for 10 min at room
temperature with 100-fold molar excess of unlabeled AP1
oligonucleotide; for supershift analysis, 2mg of antibodies
against c-Jun and c-Fos (Santa Cruz Biotechnology) were added
for 1 h at room temperature. Subsequently, binding to 10 nmol
of labeled AP1 oligo was carried out in a reaction mixture
containing 1 mg of poly(dI–dC), 10 mM Tris, pH 7.5, 50 mM
NaCl, 5% glycerol, 1 mM DTT, 1 mM EDTA for 30 min at room
temperature.
Real-time reverse transcriptase-PCR (RT-PCR)
The expression of MDR1 gene was determined using a TaqMan
based real-time PCR method. To analyze and quantify the levels
of the MDR1 gene, we used a TaqMan isoform-specific probe
(assay no. Hs00184491_m1; Applied Biosystems, Foster City,
CA, USA). Amplification was performed using a total reaction
volume of 25ml in a MicroAmp Optical 96-well reaction plate.
All real-time PCR reactions were carried out with TaqMan
Universal Master Mix. Reactions were run on the ABI Prism
7300 sequence detection system (Applied Biosystems) using the
following conditions: 50 1C for 2 min, 95 1C for 10 min, followed
by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. Quantification
analysis was performed by the DDCt method and statistically
analyzed by GraphPad Prism software.
siRNA experiments
CEM-R cells were transfected with a nucleofection device
(Amaxa Inc., Cologne, Germany), using kit C and program X-
001, according to the manufacturer’s instructions. A total of
5 106 cells were transfected with 2mg JNK small interfering
RNA (siRNA) (sc-29380; Santa Cruz Biotechnology) or aspecific
siRNA (siCONTROL riscfree no. 1; Dharmacon, Lafayette, CO,
USA). After 72 h, cells were partly analyzed for real-time RT-
PCR, and partly lysed for western blotting to assess the level of
JNK expression.
Flow cytometric detection of Ser63 p-c-Jun levels
This was performed as reported by others,25 using an anti-Ser63
p-c-Jun antibody (Cell Signaling), which was then detected with
an FITC-conjugated anti-rabbit IgG (Dako, Glostrup, Denmark).
Flow cytometric analysis of P-gp expression and P-gp
direct dye efflux assay
These were performed essentially as described.21
Results
Perifosine reduces cell viability and induces apoptosis
in wild-type and P-gp-expressing T-ALL CEM cells
CEM cells contain constitutively elevated amounts of activated
Akt, since they lack the PTEN gene.26 To determine whether
perifosine treatment would result in diminished survival and
increased apoptosis, CEM-R and CEM-S cells were incubated in
the presence of increasing concentrations of the drug for 24 h
and viability was evaluated by MTT assays. As shown in
Figure 1a, perifosine induced a dose-dependent decrease in
viability in both cell lines. At 24 h, the IC50 was 6.8mM for CEM-
S cells, while it was 19.3mM for CEM-R cells. The difference in
sensitivity to perifosine could be due to a different level of Akt
activation in these two cell lines. In fact, by western bloting and
densitometric scanning we observed that CEM-R cells had much
higher amounts of Ser473 p-Akt than CEM-S cells (Figure 1b).
Thus, for all subsequent experiments, we used perifosine
concentrations of 7mM for CEM-S and 20mM for CEM-R. It was
next investigated whether decreased survival was related to
apoptosis. In response to treatment with 7mM perifosine for 6 h,
approximately 50% of CEM-S cells were positive for Annexin V
(early apoptotic cells), whereas 2% were positive for both
Annexin-V and PI, and they represented late apoptotic/
secondary necrotic cells (Figure 1c). Also CEM-R cells exhibited
early apoptotic features when stained with Annexin V–FITC/PI.
In fact, after 6 h of treatment, 55% of the cells were early
apoptotic, whereas a 0.1% was late apoptotic/secondary
necrotic (Figure 1c). The effect of perifosine on proliferation
was analyzed at longer incubation times by direct cell counting.
Figure 4 Perifosine induces cytochrome c release from the mito-
chondria of CEM-R cells. (a) Double immunofluorescence analysis.
Control (CTRL) and perifosine-treated (20mM for 6 h) cells were fixed
and were permeabilized. They were then immunostained with an
antibody to cytochrome c (cyt. c, green) and an antibody to complex V
(red). The merged image shows colocalization of the two fluoro-
chromes (yellow-orange). Nuclei were counterstained for DNA by
40,6-diamidino-2-phenylindole. (b) Western blot analysis performed
on the purified mitochondrial fraction. The blots were probed with
antibodies to the mitochondrial marker complex IV (cytochrome c
oxidase IV) and cytochrome c (cyt. c). Molecular weights are indicated
to the right. The numbers indicate the results from densitometric
analysis. One representative of three different experiments is shown.
DAPI, 40,6-diamidino-2-phenylindole.
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Exponentially growing cells were treated with perifosine for 72 h
and viable cells were counted every day. If the drug was not
added again after 24 h of incubation, there was a slight increase
in the cell number in both cell lines beginning at 24 h
(Figure 2a). However, if cells where washed with serum-free
medium and the drug was re-added, we observed that perifosine
was able to completely block cell proliferation in both cell lines
up to 72 h.
Perifosine treatment results in downregulation of p-Akt
levels
We then focused our attention on whether the drug influenced
the expression and phosphorylation levels of Akt in CEM-R cells.
Western blotting analysis with phosphospecific Akt antibodies
demonstrated complete dephosphorylation of Akt at Ser473
already after 6 h of incubation with 20 mM perifosine, whereas
slight phosphorylation of Thr308 was still observable at 24 h of
Figure 5 Perifosine-evoked apoptosis is partly dependent on Fas/FasL interactions and lipid raft integrity. (a) Immunofluorescence analysis.
Control (CTRL) and perifosine-treated (20mM for 6 h) CEM-R cells were stained with FITC-CTx B subunit (green), and then samples were incubated
with 500 ng ml1 of anti-human Fas (SM1/1) IgG2a mouse monoclonal antibody for overnight at 4 1C, which was detected by a Cy3-conjugated
secondary antibody (red). Merging of the two fluorescent signals results in a yellow-orange color. Nuclei were counterstained for DNA by 40,6-
diamidino-2-phenylindole. (b) Representative histograms showing flow cytometric analysis of Annexin V–FITC/PI-stained cells. Cells were cultured
with perifosine (20mM) for 6 h in the presence or absence of a mouse monoclonal blocking antibody to human Fas (SM1/23, 2mg ml1). The
percentage of early apoptotic cells (lower right quadrant) and late apoptotic/necrotic cells (upper right quadrant) are indicated. One representative
of three different experiments is shown. (c) Immunofluorescence analysis showing disruption of lipid rafts in cells treated with perifosine (20mM) for
6 h in the presence or absence of methyl-b-cyclodextrin (15 mg ml1). The dot plots show Annexin V/PI staining in cells treated as above. The
percentage of early apoptotic cells (lower right quadrant) and late apoptotic/necrotic cells (upper right quadrant) are indicated. One representative
of three different experiments is shown. DAPI, 40,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; FITC-CTx B, FITC-labeled cholera
toxin-B; MCD, methyl-b-cyclodextrin; PI, propidium iodide.
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incubation (Figure 2b). In CEM-R cells, we did not detect p-ERK
1/2. Perifosine did not affect ERK 1/2 phosphorylation positively,
at variance with other reports,20,27 and total levels of ERK 1/2
were unaffected by drug treatment (Figure 2b).
Perifosine treatment induces caspase-dependent cell
death in CEM-R cells
It is well established that P-gp overexpression impairs caspase
activation.4 Our previous results highlighted that perifosine
induces caspase-dependent cell death in Jurkat T-ALL cells.20
Thus, we examined the possible activation of caspases in
perifosine-treated CEM-R cells using various approaches. Western
blotting analysis revealed that cleavage of apical procaspase-8
into the characteristic 43/41-kDa fragments was already evident
after 3 h of treatment with perifosine, and then increased. Also,
cleavage of apical procaspase-9 became evident at 3 h of
treatment and increased in a time-dependent manner. Cleavage
of procaspase-3 into the characteristic 17/19-kDa fragments was
already detectable at 3 h of treatment with the inhibitor and
displayed a time dependent increase. Caspase activation was
accompanied by cleavage of the caspase-3 substrate, PARP, and
by Bid cleavage (Figure 3a), and it was also examined by flow
cytometric analysis of FLICA-stained samples. This technique
confirmed activation of caspase-8 and caspase-3/7 by perifosine
(Figure 3b). Also, immunofluorescence staining with cleaved
caspase-3-specific antibody demonstrated caspase-3 upregulation
at 6 h of treatment (Figure 3c). Moreover, the relevance of caspase
activation for perifosine-induced apoptosis was demonstrated by
pretreatment of CEM-R cells with selective pharmacological
inhibitors of either caspase-8 or caspase-3, which markedly
attenuated apoptosis elicited by perifosine (Figure 3d). These
inhibitors induced some cytotoxicity in untreated cells. This is
consistent with a previous report indicating that caspase inhibitors
alone could induce a modest apoptosis in T-ALL cell lines.28
Perifosine induces cytochrome c release from
mitochondria
Caspase-9 and Bid cleavage suggested that the intrinsic
(mitochondrial) pathway of apoptosis could be upregulated by
perifosine in CEM-R cells. To demonstrate the involvement of
the mitochondrial pathway, we analyzed cytochrome c release
from mitochondria. Double immunofluorescence staining de-
monstrated that in untreated cells, cytochrome c and complex V
colocalized at the mitochondrial level (Figure 4a). In contrast, in
perifosine-treated cells, the two signals (green for cytochrome c
and red for complex V) were completely separated, indicating
release of cytochrome c from mitochondria.
This finding was corroborated by western blot analysis
performed on the isolated mitochondrial fraction, which
demonstrated robust decrease of cytochrome c remaining in
mitochondria, whereas the amount of the mitochondrial marker
cytochrome c oxidase IV29 did not change (Figure 4b).
Perifosine cytotoxicity in CEM-R cells is dependent on
lipid raft integrity and Fas ligation
Very recent results have highlighted that in multiple myeloma
cells, perifosine-induced apoptosis was dependent on recruit-
ment of Fas/CD95 death receptor, Fas-associated death domain-
containing protein and procaspase-8 into lipid rafts, leading to
formation of the death-inducing signaling complex.16 Thus, we
determined whether this occurred in CEM-R cells. By immuno-
Figure 6 Perifosine cytotoxicity is dependent on JNK and c-Jun activation in CEM-R cells. (a) Representative histograms showing flow cytometric
analysis of Annexin V–FITC/PI-stained cells. Cells were cultured with perifosine (20 mM) for 6 h in the presence or absence of the JNK-selective
inhibitor SP600125 (10mM). The percentage of early apoptotic cells (lower right quadrant) and late apoptotic/necrotic cells (upper right quadrant)
are indicated. One representative of three different experiments is shown. (b) Western blot analysis. Whole-cell extracts were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose, which were then probed by antibody to total JNK and Thr183/
Tyr185 p-JNK. Molecular weights are indicated to the right. One representative of three different experiments is shown. (c) Flow cytometric
detection of Ser63 p-c-Jun. CEM-R cells were treated with perifosine for 6 h, reacted with a primary antibody to p-c-Jun (Ser63) and then a
secondary FITC-conjugated secondary antibody was used. At least 15 000 events were analyzed. CTRL, untreated cells; FITC, FITC, fluorescein
isothiocyanate; JNK, c-Jun NH2-terminal kinase; PI, propidium iodide.
Perifosine toxicity in P-gp-expressing CEM cells
F Chiarini et al
1112
Leukemia
cytochemical staining, we demonstrated that, in response to
perifosine treatment, there was an increase in colocalization of
FITC-CTx B subunit, which binds ganglioside GM1 mainly
found in rafts (see Schon and Freire30), with Fas (Figure 5a).
Moreover, a Fas-blocking monoclonal antibody markedly
reduced perifosine-dependent cell death (Figure 5b). In addi-
tion, we analyzed the effect of lipid raft disruption on perifosine-
mediated apoptosis. Methyl-b-cyclodextrin treatment resulted in
disruption of lipid rafts as indicated by fluorescence microscopy
analysis of FITC-CTx B subunit-stained samples (Figure 5c).
Methyl-b-cyclodextrin interfered with protein association with
lipid rafts by cholesterol depletion,31 and resulted in a decrease
in the number of apoptotic cells (Figure 5c). Taken together,
these findings strongly suggested that in CEM-R cells, apoptotic
cell death is, at least in part, dependent on lipid raft integrity and
Fas/Fas ligand (FasL) interactions.
Perifosine activates JNK and c-Jun in CEM-R cells
Since previous findings hinted that JNK could be another
important mediator of perifosine cytoxicity in multiple myeloma
cells,27 it was investigated whether this was true also for CEM-R
cells. In cells preincubated with the JNK-selective inhibitor
SP600125 and then treated for 6 h with perifosine, there was a
marked decrease in apoptosis, as revealed by Annexin-V/PI
staining (Figure 6a). Moreover, perifosine dramatically increased
JNK phosphorylation at Thr183/Tyr185, as indicated by western
blot analysis (Figure 6b). Perifosine induced c-Jun phosphoryla-
tion at Ser63, a JNK-specific target, as demonstrated by flow
cytometric analysis of CEMR cells (Figure 6c).
Perifosine causes downregulation of MDR1 gene
expression and enhances the DNA-binding activity of
AP1 through JNK activity
We determined whether perifosine affected the expression of
P-gp. Real-time RT-PCR analysis demonstrated that transcription
of the MDR1 gene was significantly reduced by perifosine
treatment at 6 h. In contrast, treatment with the JNK inhibitor
significantly opposed the downregulation of P-gp mRNA caused
by perifosine (Figure 7a). Moreover, in cells treated with siRNA
specific for JNK, the perifosine-dependent decrease in P-gp
mRNA levels was not detected (Figure 7b). Downregulated JNK
expression by siRNA was verified by western blot analysis
(Figure 7c). The MDR1 gene promoter was previously reported
to contain an AP1-binding site, which functions as a negative
element for its regulation.32,33 We investigated AP1 activation
by electrophoretic mobility-shift assay in response to perifosine
treatment. As shown in Figure 7d, after 6 h of treatment with
perifosine, AP1-binding activity increased when compared with
untreated cells, whereas the JNK inhibitor opposed perifosine-
mediated increase in AP1 activity. Moreover, we performed gel
supershift assays. As expected, the band disappeared by addition
of the c-Jun antibody, and was strongly reduced by addition of c-
Fos antibody (Figure 7d).
Figure 7 Perifosine downregulates P-gp mRNA in CEM-R cells. (a) Real-time RT-PCR. Results are from three different experiments±s.e. One
asterisk indicates statistically significant difference (Po0.001) with respect to untreated cells (CTRL), whereas two asterisks indicate statistically
significant difference (Po0.001) with respect to cells treated with perifosine alone. (b) Real-time RT-PCR of cells treated with JNK siRNA. In this
panel, CEM-R CTRL and CEM-R 6 h TREATED were transfected with aspecific siRNA. Results are from two different experiments±s.e. (c) Western
blot analysis of JNK downregulation by siRNA. CTRL, cells were transfected with 2mg of aspecific siRNA for 72 h; ctrl.þ siRNA, cells were
transfected for 72 h with 2 mg of JNK-specific siRNA; 6 h treatedþ siRNA, cells were transfected for 72 h with 2 mg of JNK-specific siRNA and then
treated 6 h with perifosine. A 20-mg weight of protein from total cell lysate was analyzed by western blotting with the indicated antibodies. (d)
Effect of perifosine on AP1 DNA-binding activity by electrophoretic mobility-shift assay. CTRL, untreated cells; 6 h Pþ JNK inhib: perifosine-
treated cells preincubated with JNK inhibitor; 6 h P, cells treated with perifosine alone for 6 h; 6 h Pþ c-Jun, nuclear extracts from perifosine-treated
cells were preincubated with c-Jun antibody; 6 h Pþ c-Fos, nuclear extracts from perifosine-treated cells were preincubated with c-Fos antibody;
6 h PþAP1, nuclear extracts from perifosine-treated cells were preincubated with 100-fold molar excess of unlabeled AP1 oligonucleotide. One
representative of three different experiments is shown. JNK, JNK, c-Jun NH2-terminal kinase; RT-PCR, reverse transcriptase-PCR; siRNA, small
interfering RNA.
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Perifosine downregulates P-gp protein expression and
activity
Western blot analysis corroborated real-time RT-PCR assay,
showing strong decrease in P-gp protein levels at 24 h of
treatment (Figure 8a), whereas at 16 h there was a slight
decrease. Moreover, surface expression of P-gp was also
diminished at 16 h, as indicated by flow cytometric analysis
(Figure 8b). Overall, these findings indicated that perifosine is
capable of downmodulating P-gp expression at both mRNA and
protein levels, and that JNK activity plays an important role in
this phenomenon. Finally, a functional assay for P-gp activity,
based on Rhodamine 123 extrusion, demonstrated that already
at 6 h of perifosine treatment, there was a marked decrease in
P-gp activity (Figure 8c).
Discussion
Perifosine is an alkylphospholipid, a novel class of antitumor
agents. Alkylphospholipids have three main effects, which might
explain their cytotoxicity. First, they interfere with multiple
cellular processes, including phospholipid turnover and lipid-
dependent signal transduction pathways. Second, they induce
stress signaling and apoptosis through caspase activation. Third,
they inhibit survival and proliferation pathways, including those
for PI3K/Akt and ERK 1/2.23 In phase-I/II studies for advanced
solid tumors, perifosine did not cause significant hematological
toxicity.15,34 This is consistent with our recent results, which
showed no cytotoxic effect of perifosine in CD34þ hemato-
poietic precursors from healthy donors.22 Here, we have
addressed perifosine efficacy in decreasing cell survival of
PTEN-negative CEM T-ALL cells, including a subclone, which
overexpresses P-gp. Perifosine, in a dose-dependent manner,
decreased survival of both CEM-R and CEM-S cells. The IC50
was lower in CEM-S than in CEMR cells, 6.8 vs 19.3 mM,
respectively, and this could have resulted from the lower level
of Akt expression in CEM-S than in CEM-R. It should be
emphasized here that 19.3 mM perifosine corresponds to
8.9 mg ml1.17 Interestingly, during a phase-I trial of perifosine,
the maximum tolerated dose was determined to be 150 mg for
six doses load and 100 mg once daily maintenance.15 This
schedule resulted in a steady-state plasma concentration of
perifosine, which was approximately 8.8 mg ml1. Hence, the in
vitro perifosine bioactive range for CEM-R cells is within the
Figure 8 Perifosine downregulates P-gp protein expression in CEM-R cells. (a) Western blot analysis. Whole-cell extracts were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, which were then probed with antibody to
P-gp or b-actin. Molecular weights are indicated to the right. The values indicate the results from densitometric analysis. One representative of
three different experiments is shown. (b) Flow cytometric detection of surface P-gp. CEM-R cells were treated with perifosine for 6 or 16 h. A
phycoerythrin-conjugated monoclonal antibody to P-gp was used. Analysis was carried out on healthy cells, which were gated by physical
parameters (side and forward scatter). (c) Flow cytometric functional efflux activity of 170 kDa P-gp in CEM-R cells. The assay is based on extrusion
of the fluorescent P-gp substrate, Rhodamine 123. The efflux activity of P-gp is highly temperature-sensitive; P-gp functions optimally at 37 1C, but
is inactive at 4 1C. When preloaded with Rhodamine 123 and incubated at 4 1C (CTRL), CEM-R cells retained the dye and consequently exhibited
high fluorescence. Conversely, cells incubated at 37 1C (CTRL) effluxed the dye. CEM-R cells treated with perifosine (6 h treated 37 1C), showed
strong decrease in the pump activity. PE, phycoerythrin; P-gp, P-glycoprotein.
Perifosine toxicity in P-gp-expressing CEM cells
F Chiarini et al
1114
Leukemia
concentrations, which could be reached in vivo. The decreased
cell survival was due to apoptosis, as indicated by flow
cytometric analysis of samples stained with Annexin-V/PI. In
CEM-R cells, we observed a marked dephosphorylation of Akt
on both Ser473 and Thr308. Perifosine did not result in ERK 1/2
activation in CEM-R cells although in some previous studies
upregulated ERK 1/2.20,27
A remarkable finding of our investigation is that perifosine
treatment resulted in activation of multiple caspases in CEM-R
cells including apical caspase-8 and caspase-9, and executioner
caspase-3. Caspase-3 activation was accompanied by cleavage
of the caspase-3 substrate, PARP. Usually, cells overexpressing
P-gp display impaired caspase activation.4 In our experiments,
selective caspase-3 and caspase-8 pharmacological inhibitors
attenuated the percentage of CEM-R cells undergoing apoptosis
in response to perifosine. This finding indicates the relevance of
caspases in perifosine-induced cell death, but it also suggests
that caspase-independent cell death signaling pathways are
activated by the drug in CEM-R cells, as reported for other cell
types, including Jurkat T-ALL cells20 and non-small lung
carcinoma cell lines.18 Cleavage of both caspase-8 and
caspase-9 demonstrated that perifosine activated the extrinsic
as well as the intrinsic apoptotic pathway. A linkage between
the two pathways could occur via Bid. Indeed, it is well known
that active caspase-8 cleaves Bid and that truncated Bid
migrates to mitochondria where it induces cytochrome c
release. Consistently, perifosine induced Bid cleavage in CEM-
R cells. Moreover, cytochrome c release from mitochondria in
perifosine-treated CEM-R cells was demonstrated by immuno-
fluorescence staining and western blot analysis performed on
the purified mitochondrial fraction, thus indicating the intrinsic
apoptotic pathway activation. Our findings suggest that lipid raft
integrity is important for perifosine-mediated apoptosis in CEM-
R cells. However, in multiple myeloma cells, perifosine-
mediated cytotoxicity was FasL independent,16 whereas in
CEM-R cells, the perifosine proapoptotic effect was at least
partly dependent on FasL, because a blocking monoclonal
antibody, which abrogates Fas/FasL-mediated killing, signifi-
cantly enhanced survival of cells treated with the drug. Our
findings highlight that JNK activation is also important for
perifosine-mediated cytoxicity in CEM-R cells, as perifosine
increased JNK phosphorylation and a selective pharmacological
inhibitor of JNK markedly enhanced survival in perifosine-
treated cells.
We have also shown for the first time that perifosine was
capable of reducing P-gp mRNA and protein expression.
Interestingly, this phenomenon could be reverted by a JNK
inhibitor. Also, siRNA downregulation of JNK, impeded the
perifosine-evoked P-gp mRNA decrease. Albeit mRNA down-
regulation was detected as early as after 6 h of treatment, the
decrease in P-gp protein was slightly apparent at 16 h and was
extremely evident at 24 h. This most likely depends on the fact
that a P-gp half-life as long as 15–18 h has been reported in
some MDR cancer cell lines.33,35 Thus, our results are consistent
with reports highlighting that in solid tumor cell lines and K562
erythroleukemia cells, P-gp mRNA downregulation required the
catalytic activity of JNK and was mediated by the c-Jun
transcription factor.33 Accordingly, in our experiments, perifo-
sine resulted in c-Jun phosphorylation on Ser63 and activation
of AP1 transcriptional activity, which could be counteracted by
a selective JNK inhibitor. At present, the transcriptional
regulation of MDR1 gene is poorly understood. The MDR1-
gene promoter has been reported to contain a negative binding
site of the transcription factor activator protein AP1.32 Besides
AP1, other transcription factors involved in the regulation of
MDR1 gene transcription include HSF1 and MEF1. Also, tumor-
suppressor protein p53 has been both positively or negatively
implicated in regulating MDR1 transcription.1
The finding that P-gp activity was downregulated by
perifosine at 6 h (that is, a time point where P-gp protein
expression levels were not affected by the drug) is puzzling.
However, it is established that P-gp exists in lipid rafts,36 where
it displays a more active state than when localized outside
rafts.37 Since perifosine specifically accumulates in lipid rafts,38
it might be that this alkylphospholipid would somehow interfere
with P-gp activity and/or localization in lipid rafts, ensuing in
downregulation of the pump activity. Further experiments are
clearly required to investigate this issue. Activation of the PI3K/
Akt pathway is frequently observed in T-ALL patients (56%) and
likely contributes to drug resistance.39,40 In some T-ALL cases,
increased PI3K/Akt signaling could be due to PTEN-gene
hypermethylation resulting in diminished expression of the
PTEN gene.41 P-gp overexpression is also detected in T-ALL
patients (24%) and negatively correlates with complete remis-
sion achievement.42 Therefore, it is likely that some T-ALL
patients would exhibit PI3K/Akt upregulation together with P-gp
overexpression, even if this has not been shown in a conclusive
manner. In conclusion, our pre-clinical studies support the
concept that inhibition of PI3K/Akt signaling with perifosine may
have clinical application for treatment of drug resistant disease
or elimination of leukemic stem cells. At the same time, it is
difficult to state whether perifosine will have a clinical future,
since the drug has not yet been studied extensively in preclinical
models or phase-I/II trials for malignant hematological disorders.
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Progetti Strategici Università di Bologna EF 2006. JAM was
supported in part by Grant RO1CA090125 from the US National
Cancer Institute (NCI/ NIH).
References
1 Hennessy M, Spiers JP. A primer on the mechanics of P-
glycoprotein the multidrug transporter. Pharmacol Res 2007; 55:
1–15.
2 Steinbach D, Legrand O. ABC transporters and drug resistance in
leukemia: was P-gp nothing but the first head of the Hydra?
Leukemia 2007; 21: 1172–1176.
3 Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:
role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48–
58.
4 Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects
leukemia cells against caspase-dependent, but not caspase-
independent, cell death. Blood 1999; 93: 1075–1085.
5 Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T,
Eckhardt SG. The farnesyl transferase inhibitor, tipifarnib, is a
potent inhibitor of the MDR1 gene product, P-glycoprotein, and
demonstrates significant cytotoxic synergism against human
leukemia cell lines. Leukemia 2007; 21: 739–746.
6 Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R,
Deimling A et al. Onconase induces caspase-independent cell
death in chemoresistant neuroblastoma cells. Cancer Lett 2007;
250: 107–116.
7 Teraishi F, Wu S, Zhang L, Guo W, Davis JJ, Dong F et al.
Identification of a novel synthetic thiazolidin compound capable
of inducing c-Jun NH2-terminal kinase-dependent apoptosis in
human colon cancer cells. Cancer Res 2005; 65: 6380–6387.
8 Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL,
Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling path-
way and its therapeutical implications for human acute myeloid
leukemia. Leukemia 2006; 20: 911–928.
Perifosine toxicity in P-gp-expressing CEM cells
F Chiarini et al
1115
Leukemia
9 Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T
et al. The insulin-like growth factor-I receptor kinase inhibitor
NVP-AEW541 induces apoptosis in acute myeloid leukemia cells
exhibiting autocrine insulin-like growth factor-I secretion. Leuke-
mia 2007; 21: 886–896.
10 Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth
factor-I signaling promotes growth and survival of human acute
myeloid leukemia cells via the phosphoinositide 3-kinase/Akt
pathway. Leukemia 2007; 21: 1921–1930.
11 Manning BD, Cantley LC. AKT/PKB signaling: navigating down-
stream. Cell 2007; 129: 1261–1274.
12 Vazquez F, Devreotes P. Regulation of PTEN function as a PIP3
gatekeeper through membrane interaction. Cell Cycle 2006; 5:
1523–1527.
13 Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/
PKB pathway: molecular target for cancer drug discovery.
Oncogene 2005; 24: 7482–7492.
14 Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK.
Perifosine, a novel alkylphospholipid, inhibits protein kinase B
activation. Mol Cancer Ther 2003; 2: 1093–1103.
15 Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K,
Kolesar J et al. A phase I trial of perifosine (NSC 639966) on a
loading dose/maintenance dose schedule in patients with ad-
vanced cancer. Clin Cancer Res 2004; 10: 7450–7456.
16 Gajate C, Mollinedo F. Edelfosine and perifosine induce selective
apoptosis in multiple myeloma by recruitment of death receptors
and downstream signaling molecules into lipid rafts. Blood 2007;
109: 711–719.
17 Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert
S et al. Phase I and pharmacological study of daily oral
administration of perifosine (D-21266) in patients with advanced
solid tumours. Eur J Cancer 2002; 38: 1615–1621.
18 Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR et al. The
alkylphospholipid perifosine induces apoptosis of human lung
cancer cells requiring inhibition of Akt and activation of the
extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6: 2029–2038.
19 Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping
the race to develop inhibitors of the phosphoinositide 3-kinase/
Akt/mammalian target of rapamycin pathway. Clin Cancer Res
2006; 12: 679–689.
20 Nyakern M, Cappellini A, Mantovani I, Martelli AM. Synergistic
induction of apoptosis in human leukemia T cells by the Akt
inhibitor perifosine and etoposide through activation of intrinsic
and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther
2006; 5: 1559–1570.
21 Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L, Martelli
AM. Caspase-dependent cleavage of 170-kDa P-glycoprotein
during apoptosis of human T-lymphoblastoid CEM cells. J Cell
Physiol 2006; 207: 836–844.
22 Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al.
Proapoptotic activity and chemosensitizing effect of the novel Akt
inhibitor perifosine in acute myelogenous leukemia cells. Leukemia
2008; 22: 147–160.
23 Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M. Rationale
and clinical application of alkylphospholipid analogues in
combination with radiotherapy. Cancer Treat Rev 2007; 33:
191–202.
24 Faenza I, Matteucci A, Manzoli L, Billi AM, Aluigi M, Peruzzi D
et al. A role for nuclear phospholipase Cbeta 1 in cell cycle
control. J Biol Chem 2000; 275: 30520–30524.
25 Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T
et al. Multidrug resistance-associated protein 1 expression is under
the control of the phosphoinositide 3 kinase/Akt signal transduc-
tion network in human acute myelogenous leukemia blasts.
Leukemia 2007; 21: 427–438.
26 Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG.
Inhibition of phosphatidylinositol 30-kinase induces preferentially
killing of PTEN-null T leukemias through AKT pathway. Biochem
Biophys Res Commun 2004; 320: 932–938.
27 Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C
et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits
Akt and induces in vitro and in vivo cytotoxicity in human multiple
myeloma cells. Blood 2006; 107: 4053–4062.
28 Shah N, Asch RJ, Lysholm AS, Lebien TW. Enhancement of stress-
induced apoptosis in B-lineage cells by caspase-9 inhibitor. Blood
2004; 104: 2873–2878.
29 Ostermeier C, Iwata S, Michel H. Cytochrome c oxidase. Curr
Opin Struct Biol 1996; 6: 460–466.
30 Schon A, Freire E. Thermodynamics of intersubunit interactions in
cholera toxin upon binding to the oligosaccharide portion of its
cell surface receptor, ganglioside GM1. Biochemistry 1989; 28:
5019–5024.
31 Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3)
induces apoptosis through translocation and capping of Fas/CD95
into membrane rafts in human leukemic cells. Blood 2001; 98:
3860–3863.
32 Ikeguchi M, Teeter LD, Eckersberg T, Ganapathi R, Kuo MT.
Structural and functional analyses of the promoter of the murine
multidrug resistance gene mdr3/mdr1a reveal a negative element
containing the AP-1 binding site. DNA Cell Biol 1991; 10:
639–649.
33 Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC. Reversal
of P-glycoprotein-mediated multidrug resistance in cancer
cells by the c-Jun NH2-terminal kinase. Cancer Res 2006; 66:
445–452.
34 Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R et al.
A phase II trial of perifosine, an oral alkylphospholipid, in
recurrent or metastatic head and neck cancer. Cancer Biol Ther
2006; 5: 766–770.
35 Miao ZH, Ding J. Transcription factor c-Jun activation
represses mdr-1 gene expression. Cancer Res 2003; 63:
4527–4532.
36 Orlowski S, Martin S, Escargueil A. P-glycoprotein and ‘lipid rafts’:
some ambiguous mutual relationships (floating on them, building
them or meeting them by chance? Cell Mol Life Sci 2006; 63:
1038–1059.
37 Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of
cellular cholesterol alters P-glycoprotein activity in multidrug-
resistant cells. Mol Pharmacol 2004; 66: 1332–1339.
38 van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D,
Solary E, Verheij M et al. A new class of anticancer alkylpho-
spholipids uses lipid rafts as membrane gateways to induce
apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6:
2337–2345.
39 Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A,
Poggi V et al. Rapamycin stimulates apoptosis of childhood
acute lymphoblastic leukemia cells. Blood 2005; 106:
1400–1406.
40 Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M,
Cimino G et al. MDR1 protein expression is an independent
predictor of complete remission in newly diagnosed adult acute
lymphoblastic leukemia. Blood 2002; 100: 974–981.
41 Yang J, Liu J, Zheng J, Du W, He Y, Liu W et al. A reappraisal by
quantitative flow cytometry analysis of PTEN expression in acute
leukemia. Leukemia 2007; 21: 2072–2074.
42 Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A
et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at
presentation and correlation with response to induction treatment
in patients enrolled in the GIMEMA LAL 0496 protocol. Blood
2006; 107: 473–479.
Perifosine toxicity in P-gp-expressing CEM cells
F Chiarini et al
1116
Leukemia
